CSPC's SYHA1813 Research Findings Presented at ESMO

The 2023 European Society for Medical Oncology (ESMO) Congress has been convened in Madrid, Spain. The ESMO Congress, renowned as one of the most prestigious and academically influential international conferences, attracts numerous experts and scholars in the field each year.

On October 21, 2023, the research findings of the "Phase I Clinical Study of SYHA1813 in Patients with Recurrent or Advanced Solid Tumors", led by Professor Li Wenbin and his team from Beijing Tiantan Hospital, affiliated with Capital Medical University, were presented at the 2023 ESMO Congress in the form of a mini oral presentation (No: 506MO).

SYHA1813, a Class 1 novel anticancer drug candidate, is a small molecule inhibitor targeting VEGFR/CSF1R. It was developed in collaboration with CSPC and possesses both domestic and international intellectual property rights. SYHA1813 not only inhibits tumor angiogenesis by blocking the VEGFR pathway but also simultaneously targets and inhibits CSF1R kinase activity, reshaping macrophage polarity and holding potential for multi-pronged antitumor actions.

In the ongoing Phase I clinical trials, SYHA1813 has shown promising antitumor efficacy in patients with recurrent high-grade gliomas and meningiomas. Explorations are also underway for its application in other solid tumor fields.